Scroll for more

About

 

Elissa Cote
Senior Vice President of Global Strategic Marketing
and Alliance Management

 

Ms. Cote joined Sucampo in April of 2014 and is our Senior Vice President of Global Strategic Marketing and Alliance Management.  She is responsible for managing the company’s business partners as part of Sucampo’s Global Alliance Agreements to market and sell Sucampo’s lead product, AMITIZA, and supports all commercial planning and global strategic marketing responsibilities for the organization both for commercial-stage and pipeline-stage opportunities.

Prior to joining Sucampo, Ms. Cote was Vice President of Marketing and Investor Relations at Histogenics, Corporation.  Ms. Cote was part of the executive team responsible for completing the company’s initial public offering (IPO), and was also responsible for all marketing activities and commercialization planning for Histogenics.

Ms. Cote previously was at MedImmune LLC, the global biologics arm of AstraZeneca and held several global commercial and leadership positions within the in-line business for the company’s RSV and influenza franchises, as well as supporting the global strategic marketing of key early and late-stage pipeline programs in the Respiratory, Autoimmune and Inflammatory Therapeutic Area.

From 1996 to 2007, Ms. Cote worked at Accenture, LLP where she served in increasing leadership roles as a senior strategic and IT consultant for global multi-million dollar corporations and clients in the public sector.  Ms. Cote earned a bachelor’s degree in Political Science from Union College.

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.